- cafead   Apr 29, 2024 at 11:22: AM
via AstraZeneca and Daiichi Sankyo have announced that their therapy Enhertu has shown a statistically and clinically meaningful progression-free survival (PFS) improvement in patients with HR-positive, HER2-low metastatic breast cancer.
article source
article source